Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review

被引:19
作者
Ayash, LJ
Clarke, M
Silver, SM
Braun, T
Uberti, J
Ratanatharathorn, V
Reynolds, C
Ferrara, J
Broun, ER
Adams, PT
机构
[1] Univ Michigan, Med Ctr, Sch Med, Dept Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Jewish Hosp Cincinnati, BMT Program, Cincinnati, OH USA
关键词
testicular cancer; tandem transplant; long-term remission;
D O I
10.1038/sj.bmt.1703008
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Testicular cancer patients refractory or in relapse after primary chemotherapy have less than or equal to 25% 5-year progression-free survival with salvage. To improve prognosis, patients entered a phase I/II tandem dose-escalation trial of carboplatin (1500-2100 mg/m(2)) and etoposide (1200-2250 mg/m(2)) with ABMT, Patients were eligible for a second cycle if disease progression was absent and performance status allowed. From August 1990 to June 1998, 29 males (25 NSGCT) were treated. At the time of ABMT, 10 were chemosensitive, four were chemoresistant, and 10 were absolutely refractory to platinum. Disease status (no, patients) at transplant: primary refractory disease (six), first relapse (10), second relapse (eight), third relapse (five). Fifteen (52%) received both transplants. Treatment-related mortality was 10%. Best response after ABMT included: two CR, one CR surgically NED, five PR, three PR surgically NED, seven SD, and eight PD, Eight (28%) patients are continuously progression-free a median 60 months (range, 31-93) from first ABMT. Three seminoma patients remain progression-free. Of five long-term NSGCT survivors, four were treated in first relapse with platinum-sensitive disease, Eighteen relapses occurred a median of 4 months after ABMT I (two late relapses at 28 and 44 months), The median PFS and OS for the whole group are 4 and 14 months, respectively. Patients with relapsed/refractory testicular cancer benefit most from ABMT if they have platinum-sensitive disease in first relapse. Patients who do poorly despite ABMT have a mediastinal primary site, true cisplatin-refractory disease, disease progression prior to ABMT, and/or markedly elevated beta HCG at ABMT. New treatment modalities are needed for the latter group.
引用
收藏
页码:939 / 947
页数:9
相关论文
共 57 条
  • [1] ADAMS PT, 1998, P AM SOC CLIN ONCOL, V17, pA325
  • [2] Armitage P, 1987, Statistical methods in medical research, V2nd
  • [3] RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY
    BAJORIN, DF
    SAROSDY, MF
    PFISTER, DG
    MAZUMDAR, M
    MOTZER, RJ
    SCHER, HI
    GELLER, NL
    FAIR, WR
    HERR, H
    SOGANI, P
    SHEINFELD, J
    RUSSO, P
    VLAMIS, V
    CAREY, R
    VOGELZANG, NJ
    CRAWFORD, ED
    BOSL, GJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) : 598 - 606
  • [4] HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH POOR-PROGNOSIS NONSEMINOMATOUS GERM-CELL TUMORS
    BARNETT, MJ
    COPPIN, CML
    MURRAY, N
    NEVILL, TJ
    REECE, DE
    KLINGEMANN, HG
    SHEPHERD, JD
    NANTEL, SH
    SUTHERLAND, HJ
    PHILLIPS, GL
    [J]. BRITISH JOURNAL OF CANCER, 1993, 68 (03) : 594 - 598
  • [5] High-dose chemotherapy as salvage treatment in germ cell tumors: A Multivariate analysis of prognostic variables
    Beyer, J
    Kramar, A
    Mandanas, R
    Linkesch, W
    Greinix, A
    Droz, JP
    Pico, JL
    Diehl, A
    Bokemeyer, C
    Schmoll, HJ
    Nichols, CR
    Einhorn, LH
    Siegert, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2638 - 2645
  • [6] BHATIA S, 1998, P AN M AM SOC CLIN, V17, pA321
  • [7] PROGNOSTIC FACTORS FOR FAVORABLE OUTCOME IN DISSEMINATED GERM-CELL TUMORS
    BIRCH, R
    WILLIAMS, S
    CONE, A
    EINHORN, L
    ROARK, P
    TURNER, S
    GRECO, FA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) : 400 - 407
  • [8] BOSL GJ, 1983, CANCER RES, V43, P3403
  • [9] Testicular germ-cell cancer
    Bosl, GJ
    Motzer, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (04) : 242 - 253
  • [10] A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS
    BOSL, GJ
    GELLER, NL
    BAJORIN, D
    LEITNER, SP
    YAGODA, A
    GOLBEY, RB
    SCHER, H
    VOGELZANG, NJ
    AUMAN, J
    CAREY, R
    FAIR, WR
    HERR, H
    MORSE, M
    SOGANI, P
    WHITMORE, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) : 1231 - 1238